Expanded Access for PSV Personalized Oncolytic Viruses

Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients

NCT01611974 ·Status: COMPLETED ·Phase: PHASE2

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

NCT00509691 ·Status: COMPLETED ·Phase: PHASE1

PTH - Preemptive Treatment for Herpesviridae

NCT02152358 ·Status: COMPLETED ·Phase: PHASE4

Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection

NCT02087306 ·Status: COMPLETED ·Phase: PHASE3

Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell

NCT06575374 ·Status: RECRUITING ·Phase: PHASE2

Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis

NCT04706507 ·Status: TERMINATED ·Phase: PHASE3

Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation

NCT00045292 ·Status: COMPLETED ·Phase: PHASE3

A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus

NCT00002095 ·Status: COMPLETED ·Phase: NA

Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant

NCT00530218 ·Status: COMPLETED ·Phase: PHASE2

Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease

NCT03010332 ·Status: NO_LONGER_AVAILABLE

A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure

NCT00000691 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir

NCT02931539 ·Status: COMPLETED ·Phase: PHASE3

Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection

NCT00017784 ·Status: UNKNOWN ·Phase: PHASE3

Maribavir for Prevention of CMV After Stem Cell Transplants

NCT00223925 ·Status: COMPLETED ·Phase: PHASE2

A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium)

NCT00002125 ·Status: COMPLETED ·Phase: PHASE4

Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure

NCT01335932 ·Status: COMPLETED ·Phase: PHASE2

Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV

NCT00006145 ·Status: COMPLETED ·Phase: PHASE3

CMX001 in Post-transplant Patients With BK Virus Viruria

NCT00793598 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Safety and Efficacy Study of a New Antiviral Drug to Prevent Cytomegalovirus Reactivation in Bone Marrow Transplanted Patients

NCT01063829 ·Status: COMPLETED ·Phase: PHASE2

VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients

NCT00431353 ·Status: COMPLETED ·Phase: PHASE4

Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection

NCT03728426 ·Status: COMPLETED ·Phase: PHASE2

Cytomegalovirus Vaccine in Healthy Participants

NCT00712634 ·Status: COMPLETED ·Phase: PHASE1

Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis

NCT06058858 ·Status: RECRUITING

Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors

NCT00353977 ·Status: COMPLETED ·Phase: PHASE2

Open Label Trial of Oral Letermovir for CMV Prophylaxis in Thoracic Transplant Recipients

NCT06066957 ·Status: RECRUITING ·Phase: PHASE2